I
Ian J. Welsby
Researcher at Duke University
Publications - 154
Citations - 4898
Ian J. Welsby is an academic researcher from Duke University. The author has contributed to research in topics: Perioperative & Cardiopulmonary bypass. The author has an hindex of 35, co-authored 147 publications receiving 4042 citations. Previous affiliations of Ian J. Welsby include Veterans Health Administration & Durham University.
Papers
More filters
Journal ArticleDOI
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
Dominick J. Angiolillo,Michael S. Firstenberg,Matthew J. Price,Pradyumna E. Tummala,Martin Hutyra,Ian J. Welsby,Michele D. Voeltz,Harish Chandna,Chandrashekhar Ramaiah,Miroslav Brtko,Louis Cannon,Cornelius M. Dyke,Tiepu Liu,Gilles Montalescot,Steven V. Manoukian,Jayne Prats,Eric J. Topol +16 more
TL;DR: Among patients who discontinue thienopyridine therapy prior to cardiac surgery, the use of cangrelor compared with placebo resulted in a higher rate of maintenance of platelet inhibition.
Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery
Dominick J. Angiolillo,Michael S. Firstenberg,Matthew J. Price,Pradyumna E. Tummala,Martin Hutyra,Ian J. Welsby,Michele D. Voeltz,Harish Chandna,Chandrashekhar Ramaiah,Miroslav Brtko,Louis Cannon,Cornelius M. Dyke,Tiepu Liu,Gilles Montalescot,Steven V. Manoukian,Jayne Prats,Eric J. Topol +16 more
TL;DR: Cagalj et al. as discussed by the authors evaluated the use of cangrelor, an intravenous, reversible P2Y(12) platelet inhibitor for bridging thienopyridine-treated patients to coronary artery bypass grafting (CABG) surgery.
Journal ArticleDOI
Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy.
TL;DR: Results show that fibrinogen concentrate is associated with a reduction or even total avoidance of allogeneic blood product transfusion, and represents an important option for the treatment of coagulopathic bleeding; further studies are needed to determine precise dosing strategies and thresholds for fibr inogen supplementation.
Journal ArticleDOI
The use of a postoperative morbidity survey to evaluate patients with prolonged hospitalization after routine, moderate-risk, elective surgery.
Elliott Bennett-Guerrero,Ian J. Welsby,T. J. Dunn,Lisa R. Young,T. A. Wahl,T. L. Diers,Barbara Phillips-Bute,Mark F. Newman,Michael G. Mythen +8 more
TL;DR: It is found that complications after routine, moderate-risk, elective surgery are common and involve multiple organ systems, and the 9-point survey can be used by healthcare providers and payers to characterize postoperative morbidity in their respective settings.
Journal ArticleDOI
The Effect of Aprotinin on Outcome after Coronary-Artery Bypass Grafting
Andrew D. Shaw,Mark Stafford-Smith,William D. White,Barbara Phillips-Bute,Madhav Swaminathan,Carmelo A. Milano,Ian J. Welsby,Solomon Aronson,Joseph P. Mathew,Eric D. Peterson,Mark F. Newman +10 more
TL;DR: Patients who received aprotinin had a higher mortality rate and larger increases in serum creatinine levels than those who received aminocaproic acid or no antifibrinolytic agent.